Literature DB >> 25437562

Structure and cancer immunotherapy of the B7 family member B7x.

Hyungjun Jeon1, Vladimir Vigdorovich1, Sarah C Garrett-Thomson2, Murali Janakiram3, Udupi A Ramagopal2, Yael M Abadi1, Jun Sik Lee1, Lisa Scandiuzzi1, Kim C Ohaegbulam1, Jordan M Chinai1, Ruihua Zhao1, Yu Yao4, Ying Mao4, Joseph A Sparano3, Steven C Almo5, Xingxing Zang6.   

Abstract

B7x (B7-H4 or B7S1) is a member of the B7 family that can inhibit T cell function. B7x protein is absent in most normal human tissues and immune cells, but it is overexpressed in human cancers and often correlates with negative clinical outcome. The expression pattern and function of B7x suggest that it may be a potent immunosuppressive pathway in human cancers. Here, we determined the crystal structure of the human B7x immunoglobulin variable (IgV) domain at 1.59 Å resolution and mapped the epitopes recognized by monoclonal antibodies. We developed an in vivo system to screen therapeutic monoclonal antibodies against B7x and found that the clone 1H3 significantly inhibited growth of B7x-expressing tumors in vivo via multiple mechanisms. Furthermore, the surviving mice given 1H3 treatment were resistant to tumor rechallenge. Our data suggest that targeting B7x on tumors is a promising cancer immunotherapy and humanized 1H3 may be efficacious for immunotherapy of human cancers.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25437562      PMCID: PMC4250833          DOI: 10.1016/j.celrep.2014.09.053

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  55 in total

1.  Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer.

Authors:  Jingting Jiang; Yibei Zhu; Changping Wu; Yueping Shen; Wenxiang Wei; Lujun Chen; Xiao Zheng; Jing Sun; Binfeng Lu; Xueguang Zhang
Journal:  Cancer Immunol Immunother       Date:  2010-08-20       Impact factor: 6.968

Review 2.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

Review 5.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

6.  Structure and T cell inhibition properties of B7 family member, B7-H3.

Authors:  Vladimir Vigdorovich; Udupi A Ramagopal; Eszter Lázár-Molnár; Eliezer Sylvestre; Jun Sik Lee; Kimberly A Hofmeyer; Xingxing Zang; Stanley G Nathenson; Steven C Almo
Journal:  Structure       Date:  2013-04-11       Impact factor: 5.006

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

9.  Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Authors:  Nida S Awadallah; Kenneth R Shroyer; Daniel A Langer; Kathleen C Torkko; Yang K Chen; Joel S Bentz; Jackie Papkoff; Wenhui Liu; S Russell Nash; Raj J Shah
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

Review 10.  Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.

Authors:  Ugo Fiocco; Paolo Sfriso; Francesca Oliviero; Elisa Pagnin; Elena Scagliori; Carla Campana; Serena Dainese; Luisella Cozzi; Leonardo Punzi
Journal:  Autoimmun Rev       Date:  2008-08-15       Impact factor: 9.754

View more
  34 in total

1.  Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Authors:  Jenessa B Smith; Evripidis Lanitis; Denarda Dangaj; Elizabeth Buza; Mathilde Poussin; Caitlin Stashwick; Nathalie Scholler; Daniel J Powell
Journal:  Mol Ther       Date:  2016-07-21       Impact factor: 11.454

2.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

3.  Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Authors:  Asim Saha; Patricia A Taylor; Christopher J Lees; Angela Panoskaltsis-Mortari; Mark J Osborn; Colby J Feser; Govindarajan Thangavelu; Wolfgang Melchinger; Yosef Refaeli; Geoffrey R Hill; David H Munn; William J Murphy; Jonathan S Serody; Ivan Maillard; Katharina Kreymborg; Marcel van den Brink; Chen Dong; Shuyu Huang; Xingxing Zang; James P Allison; Robert Zeiser; Bruce R Blazar
Journal:  JCI Insight       Date:  2019-10-03

Review 4.  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Authors:  Alexander Sankin; Deepa Narasimhulu; Peter John; Benjamin Gartrell; Mark Schoenberg; Xingxing Zang
Journal:  Urol Oncol       Date:  2017-05-08       Impact factor: 3.498

5.  NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion.

Authors:  Liwen Li; Lei Han; Fan Sun; Jingjiao Zhou; Kim C Ohaegbulam; Xudong Tang; Xingxing Zang; Kris A Steinbrecher; Zhaoxia Qu; Gutian Xiao
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

8.  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Authors:  Haiying Cheng; Alain Borczuk; Murali Janakiram; Xiaoxin Ren; Juan Lin; Amer Assal; Balazs Halmos; Roman Perez-Soler; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2018-01-26       Impact factor: 12.531

Review 9.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 10.  Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

Authors:  Amer Assal; Justin Kaner; Gopichand Pendurti; Xingxing Zang
Journal:  Immunotherapy       Date:  2015-11-16       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.